What Is HPV?

Human papillomavirus (HPV) is a group of more than 200 related viruses, of which approximately 40 strains are transmitted through sexual contact. According to the Centers for Disease Control and Prevention (CDC), nearly 80 million Americans are currently infected with HPV, and about 14 million new infections occur every year. In fact, the CDC estimates that nearly every sexually active person will contract HPV at some point in their lifetime.

Most HPV infections clear on their own within 1 to 2 years without causing any health problems. However, certain high-risk strains, particularly HPV 16 and HPV 18 can persist and lead to cervical cancer and other serious conditions if left undetected.

Signs You May Have HPV

Here is what makes HPV unique: it often has no symptoms at all. Many women carry HPV for years without knowing it. However, some signs to watch for include:

• Genital warts — soft, flesh-colored growths in or around the vaginal area, cervix, or anus. These are caused by low-risk HPV strains (types 6 and 11) and do not cause cancer, but they do require treatment.
• Abnormal Pap smear results — often the first indicator of a high-risk HPV infection, detected during routine gynecological screening
• Abnormal vaginal bleeding — bleeding between periods, after intercourse, or after menopause can sometimes signal HPV-related cervical changes
• Unexplained pelvic discomfort — though less common, persistent pelvic pain warrants evaluation

If you are experiencing any of these symptoms or simply have concerns  do not wait. See your OB-GYN.

What to Do First: Get Tested

The most important step you can take is scheduling a cervical cancer screening with your OB-GYN. There are two key tests:

Pap Smear (Pap Test) A Pap smear collects cells from your cervix to check for abnormal changes that could develop into cervical cancer. The American Cancer Society recommends Pap smears beginning at age 21, repeated every 3 years for women ages 21–65.

HPV DNA Test (Co-Testing) The HPV test detects the presence of high-risk HPV strains directly. For women 30 and older, co-testing, a Pap smear combined with an HPV DNA test is the gold standard for cervical cancer screening. A landmark study published in the New England Journal of Medicine found that HPV-based screening was significantly more effective at detecting precancerous cervical lesions than cytology alone.

What Happens If Your Results Are Abnormal?

An abnormal result does not mean you have cancer. It means your OB-GYN needs to look more closely. Next steps may include:

• Colposcopy — a detailed examination of the cervix using a magnifying instrument to identify abnormal areas
• Cervical biopsy — a small tissue sample taken during colposcopy to determine the grade of any cell changes (called CIN — cervical intraepithelial neoplasia)
• LEEP procedure (Loop Electrosurgical Excision Procedure) — removes abnormal cervical tissue if precancerous cells are found. Research shows LEEP is highly effective, with success rates of 90–95% for treating high-grade cervical dysplasia (ASCCP Guidelines, 2019)

HPV Treatment: What You Need to Know

There is currently no cure for the HPV virus itself,  but there are highly effective treatments for the conditions it causes:

• Genital warts are treated with topical medications, cryotherapy (freezing), or minor surgical removal
• Precancerous cervical changes are treated with LEEP, cryotherapy, or cone biopsy depending on severity
• Persistent high-risk HPV is managed through close monitoring and follow-up with your OB-GYN
• Cervical cancer, if detected at an early stage, has a 5-year survival rate of over 92%, according to the American Cancer Society,  which is why regular screening is life-saving

The HPV Vaccine: Still an Option for Many Women

If you have not been vaccinated, the HPV vaccine (Gardasil 9) is FDA-approved for women up to age 45. It protects against nine HPV strains, including the two highest-risk strains (HPV 16 and 18) responsible for approximately 70% of cervical cancers. A major study published in The Lancet confirmed that the HPV vaccine reduces the risk of high-grade cervical lesions by up to 87% in previously uninfected women.

Even if you already have HPV, the vaccine can protect you against strains you have not yet been exposed to. Talk to your OB-GYN about whether vaccination is right for you.

Protecting Your Health Going Forward

A diagnosis of HPV is not the end of the story,  it is the beginning of proactive care. Here is what you can do:

• Keep all follow-up appointments — consistent monitoring is the most effective way to catch any changes early
• Do not smoke — smoking significantly weakens the immune system’s ability to clear HPV and increases the risk of cervical cancer progression
• Practice safe sex — consistent condom use reduces (but does not eliminate) the risk of HPV transmission
• Talk to your partner — HPV is extremely common and can be transmitted even without symptoms
• Stay current on screenings — regular Pap smears and HPV co-testing are your most powerful protection

The Bottom Line

Suspecting or being diagnosed with HPV can feel frightening  but knowledge is power. Most HPV infections resolve on their own, and with proper screening, monitoring, and care, serious complications are highly preventable. The women who protect their health best are those who stay informed, stay screened, and work closely with a trusted OB-GYN.

Schedule Your Women’s Health Appointment with IVANA MD

If you suspect you have HPV, have received an abnormal Pap result, or are simply overdue for a cervical cancer screening, do not wait. Our experienced women’s health team in Missouri City, TX is here to provide compassionate, confidential, and expert care.

Call: 346-585-4077

4220 Cartwright Road, Suite 201, Missouri City, Texas 77459

Compassionate. Evidence-based. Personalized. That is IVANA MD.

This blog is for educational purposes only and does not constitute medical advice. Always consult a qualified women’s health provider for HPV screening, evaluation, and treatment.

References

• Centers for Disease Control and Prevention. (2023). HPV Fact Sheet. www.cdc.gov/std/hpv
• Ronco G, et al. (2014). Efficacy of HPV-based screening for prevention of invasive cervical cancer. New England Journal of Medicine, 371, 819–827.
• American Cancer Society. (2023). Cervical Cancer Survival Rates. www.cancer.org
• ASCCP. (2019). Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests. Journal of Lower Genital Tract Disease, 24(2), 102–131.
• Kjaer SK, et al. (2020). Final analysis of a 14-year long-term follow-up study of the HPV vaccine. The Lancet, 395, 1908–1916.

The post What to Do if You Suspect HPV: A Complete Guide for Women  appeared first on IvanaMd.

“Am I too young for menopause?” “Could what I am experiencing be perimenopause?” “My mother went through it at 45, will I?”

These are some of the most common and most important questions women bring to their healthcare providers and yet, many leave their appointments without the complete, honest answers they deserve.

The truth about when menopause starts is more nuanced, more variable, and more scientifically rich than the simple number “51”  most women have heard. Understanding the real age range, the factors that influence your personal timing, the difference between perimenopause and menopause, and when early or late menopause warrants medical attention can fundamentally change how you approach your own reproductive health and long-term wellbeing.

According to the World Health Organization (WHO), menopause affects every woman who lives long enough to experience it. Yet the timing of this universal transition varies by as much as two decades between individuals, a range far wider than most women realize. A woman whose periods stop at 40 and a woman whose periods stop at 58 are both experiencing natural menopause yet their health implications, treatment needs, and reproductive considerations are dramatically different.

This guide brings the full scientific picture into focus so you can understand where you are in your journey and what it means for your health.

Defining the Terms: Perimenopause, Menopause, and Postmenopause

To understand when menopause starts, it is essential to understand that “menopause” is not a single event, it is a multi-phase biological transition that unfolds over years, sometimes decades.

Perimenopause — The Transition That Begins Long Before the Last Period

Perimenopause — derived from the Greek peri, meaning “around”, is the transitional phase during which ovarian function begins to decline, hormone levels fluctuate, and menstrual cycles become irregular. It begins before the final menstrual period and is clinically characterized by:

• Cycle irregularity — cycles shortening, lengthening, or varying unpredictably
• Vasomotor symptoms — hot flashes and night sweats
• Mood and sleep changes
• Changes in flow — lighter or heavier than usual
• Hormonal fluctuations — FSH beginning to rise, estradiol becoming erratic

The Stages of Reproductive Aging Workshop (STRAW +10) — the internationally recognized scientific framework for classifying reproductive aging, updated in 2011 and published in the Journal of Clinical Endocrinology & Metabolism — divides the menopausal transition into two stages:

• Early transition: Cycle length variability of 7 or more days from the normal cycle length; FSH beginning to rise
• Late transition: Two or more skipped cycles and an interval of 60 or more days between periods; marked hormonal fluctuation

The STRAW +10 framework is the global clinical and research standard for staging where a woman is in the menopausal transition — and understanding it helps explain why “perimenopause” can feel so different from woman to woman.

Menopause — The Marker, Not the Beginning

Menopause itself is a retrospective diagnosis. It is defined as 12 consecutive months without a menstrual period, not attributable to any other cause (pregnancy, illness, medication, extreme stress). This single marker,  the 12-month anniversary of the last period is the formal boundary between perimenopause and postmenopause.

Critically: a woman does not “enter menopause” when she has her last period. She only knows it was her last period 12 months later. This is why menopause can feel like a moving target and why symptoms during the years before the final period (perimenopause) are so frequently unrecognized.

Postmenopause — All Years Following the Final Period

Postmenopause encompasses the remainder of a woman’s life after the confirmed final menstrual period. With average female life expectancy in the United States now exceeding 81 years, most women will spend 30 or more years of their life in the postmenopausal phase. This extended postmenopausal lifespan underscores the enormous long-term health significance of the menopausal transition.

The Average Age of Menopause: What the Research Shows

The most cited figure and the most accurate population average  is 51.4 years for natural menopause in the United States.

This figure comes from multiple large epidemiological studies, including the landmark Study of Women’s Health Across the Nation (SWAN), which followed over 3,000 women across multiple ethnic and racial backgrounds. Findings from the SWAN study, published across numerous papers in journals including American Journal of Epidemiology and Menopause, established a natural menopause age range of 40–58 years, with the vast majority of women (approximately 95%) experiencing menopause between ages 44 and 56.

A large-scale systematic review published in a Human Reproduction Update analyzed data from over 300,000 women across 11 countries  confirmed that the median age of natural menopause globally was 48.8 to 52.5 years, depending on geographic region, ethnicity, and study methodology.

What the age of 51 actually represents: It is the median, the midpoint of a distribution. Approximately half of women reach menopause before 51, and half after. A woman experiencing her final menstrual period at 47 is not experiencing “early” menopause in the clinical sense; she is in the lower half of the normal range. A woman whose periods continue to 55 is in the upper half of the normal range  and both are entirely within the expected spectrum of natural variation.

When Perimenopause Actually Begins: Earlier Than Most Women Expect

If the average age of menopause is 51, and perimenopause typically begins 4–10 years before the final period,  then perimenopause, on average, begins between ages 41 and 47.

The SWAN study found that perimenopause began at a median age of approximately 47.5 years, though individual variation was substantial. A significant proportion of women in the study noticed first symptoms of the transition, particularly cycle changes, sleep disruption, mood shifts, and early vasomotor symptoms  in their late 30s or early 40s.

This has profound clinical implications: millions of women in their late 30s and early 40s are experiencing perimenopause symptoms without recognizing them. Irregular periods, new-onset anxiety, disrupted sleep, unexplained fatigue, and mood changes in a 39-year-old are not necessarily psychiatric or stress-related; they may be the first signs of the menopausal transition. 

The most common reason these symptoms go unrecognized?

Healthcare providers and women themselves often do not consider perimenopause as a possibility in women under 45. This represents one of the most significant and costly gaps in women’s healthcare.

The Full Age Spectrum: From Premature to Late Menopause

Premature Ovarian Insufficiency (POI) — Menopause Before Age 40

Premature ovarian insufficiency (POI) — previously termed “premature menopause” is defined as the cessation of normal ovarian function before age 40, characterized by amenorrhea (absent periods) and elevated FSH levels confirming ovarian insufficiency.

POI affects approximately 1% of women under age 40 and 0.1% of women under age 30, according to the American Society for Reproductive Medicine (ASRM). A landmark epidemiological study published in the New England Journal of Medicine (2009) by Coulam et al. confirmed these prevalence estimates across multiple population cohorts.

POI is not the same as natural menopause. In many women with POI, ovarian function is intermittent meaning sporadic ovulation can still occur, and spontaneous pregnancy remains possible in approximately 5–10% of women with POI, according to research in Human Reproduction (2010). However, ovarian function is severely diminished, and without treatment, the long-term consequences of early estrogen deficiency are substantial.

The long-term health consequences of POI without hormone therapy are serious:

• Bone loss at a rate and magnitude significantly greater than natural menopause  leading to premature osteoporosis
• Cardiovascular disease risk substantially elevated from decades of estrogen deficiency
• Cognitive and neurological consequences — research published in Neurology  found that women with untreated POI had significantly accelerated cognitive decline compared to women with natural menopause
• Premature mortality — a large meta-analysis published in Human Reproduction Update (2016) by Zhu et al. found that women with POI had significantly higher all-cause and cardiovascular mortality compared to women with natural menopause  an excess mortality that was substantially mitigated by hormone therapy use

This is why hormone therapy is strongly and specifically recommended for women with POI — not merely as symptom relief, but as essential health maintenance — with most guidelines recommending continuation until at least the average age of natural menopause (51 years).

Causes of POI include:

• Genetic factors — including Turner syndrome (45,X), Fragile X premutation carriers, and other chromosomal variations
• Autoimmune conditions — POI is associated with autoimmune thyroid disease (Hashimoto’s, Graves’), Addison’s disease, type 1 diabetes, and other autoimmune disorders
• Iatrogenic causes — chemotherapy (particularly alkylating agents), radiation to the pelvic region, and bilateral oophorectomy (surgical removal of both ovaries)
• Idiopathic — in approximately 50% of cases, no identifiable cause is found

Early Menopause — Ages 40 to 45

Natural menopause occurring between ages 40 and 45 is termed early menopause  distinct from POI (before 40), but still associated with a longer duration of estrogen deficiency and elevated long-term health risks compared to menopause at the average age.

Early menopause affects approximately 5% of women, according to data published in Maturitas (2015). Its health implications are significant:

A large population-based study published in JAMA Internal Medicine (2015) by Mishra et al. analyzing data from 5,107 women found that each year of earlier menopause was associated with a 2% increase in cardiovascular risk. Women with early menopause had significantly higher rates of coronary heart disease, stroke, and cardiovascular mortality compared to women with average-age menopause.

Research in Menopause (2016) by Zhu et al. additionally confirmed that early menopause was associated with elevated risks of osteoporosis, cognitive decline, and depression reinforcing the clinical importance of early recognition and prompt, appropriate management.

Natural Menopause — Ages 45 to 55

The broad central range of natural menopause encompasses the majority of women. Within this range:

• Ages 45–50: Somewhat earlier than average, but entirely within the normal spectrum. No elevated long-term health risk beyond that of natural menopause itself.
• Ages 50–55: The most populous range, including the median age of 51.4. Consistent with the expected trajectory.
• Ages 55–58: Later than average but still within the upper limit of normal. Associated in several studies with modest reductions in certain health risks (see below).

Late Menopause — After Age 55

Natural menopause occurring after age 55  affecting approximately 5% of women  is termed late menopause. Interestingly, later menopause carries a nuanced risk-benefit profile:

Potential benefits of late menopause:

• Reduced osteoporosis risk — extended estrogen exposure maintains bone density longer
• Reduced cardiovascular risk from longer estrogen protection
• Possible cognitive benefit — longer estrogen exposure may support neurological health
• Some evidence of greater longevity — a study published in Menopause (2013) found that women with later natural menopause had modestly longer overall life expectancy

Potential risks of late menopause:

• Elevated breast cancer risk — each additional year of menstruation beyond the average represents continued exposure to endogenous estrogen and progesterone, which is associated with a small but measurable increase in hormone-receptor-positive breast cancer risk. A large analysis published in The Lancet Oncology (2012) confirmed this association.
• Elevated endometrial cancer risk — prolonged estrogen stimulation of the uterine lining increases endometrial hyperplasia and cancer risk in women without adequate progestogen protection

Any vaginal bleeding occurring after confirmed menopause (12+ months without a period) must be evaluated promptly, regardless of age to exclude endometrial cancer.

What Determines When You Will Go Through Menopause?

This is one of the most frequently asked and most scientifically fascinating questions in menopause medicine. The timing of menopause is influenced by a complex interplay of genetic, lifestyle, reproductive, and environmental factors.

Genetics — The Single Strongest Predictor

Research consistently shows that genetics accounts for approximately 50–85% of the variance in menopause timing, making your mother’s menopause age the most reliable predictor of your own.

A landmark genome-wide association study (GWAS) published in Nature Genetics (2021) by Ruth et al. analyzed data from over 200,000 women across 17 countries  identified 290 genetic variants associated with menopause timing, involving genes related to DNA repair, cell cycle regulation, and immune function. This study demonstrated that natural menopause timing is genetically complex and multifactorial.

A study in Obstetrics & Gynecology (2005) by Torgerson et al. found that women whose mothers experienced early menopause were six times more likely to experience early menopause themselves, a striking intergenerational correlation.

Practical implication: Ask your mother, maternal grandmother, and maternal aunts when they went through menopause. This family history is important medical information particularly if multiple relatives had early menopause.

Smoking — The Most Impactful Modifiable Factor

Cigarette smoking consistently advances menopause timing. The mechanism is well-established: tobacco’s polycyclic aromatic hydrocarbons have direct ovotoxic effects, accelerating follicular atresia (the depletion of the ovarian follicle reserve).

A comprehensive meta-analysis published in Maturitas (2014) by Sapre and Thakur analyzing data from over 40 studies  found that current smokers reached menopause an average of 1.5–2 years earlier than non-smokers. Former smokers showed partial risk reversal, but the damage from years of smoking is not fully reversible.

This represents one of the few modifiable lifestyle factors with a documented, direct effect on ovarian aging, a compelling additional reason to address smoking cessation in women’s preventive healthcare.

Body Mass Index (BMI) and Body Fat

Body fat is a site of peripheral estrogen synthesis. Adipose tissue contains the enzyme aromatase, which converts androgens to estrogens providing an additional estrogen source in overweight and obese women.

Research published in the American Journal of Epidemiology (2014) found that higher BMI was modestly associated with later menopause, while lower BMI (underweight) was associated with earlier menopause. Women with very low body weight, including those with a history of restrictive eating disorders or extreme athletic training — may experience earlier menopause or amenorrhea due to insufficient estrogen substrate.

Reproductive History — Pregnancies, Breastfeeding, and Oral Contraceptive Use

Parity (number of pregnancies): Research suggests that women who have been pregnant may have a modestly later menopause compared to a woman that has never given birth. The theory is that pregnancy suppresses ovulation, effectively “pausing” the clock on follicular depletion. A study in Human Reproduction (2010) by Cramer et al. found that each additional pregnancy was associated with a modest delay in menopause age.

Oral contraceptive use: Oral contraceptives suppress ovulation, potentially slowing the rate of follicular depletion. Some studies suggest long-term OCP users experience slightly later menopause, though the effect is modest and findings are not entirely consistent.

Breastfeeding: Similar to OCP use and pregnancy, lactation suppresses ovulation, which may modestly delay the pace of ovarian aging.

Ethnicity and Race

The SWAN study was uniquely designed to capture ethnic and racial variation in menopausal timing and symptom experience and its findings are clinically important.

Key findings from SWAN and subsequent analyses published in American Journal of Epidemiology (2008):

• Hispanic women reached menopause at a median age of 50.0 years — somewhat earlier than the overall average
• African American women: 49.3 years — the earliest among the groups studied — with additional findings of greater symptom severity and longer vasomotor symptom duration
• Caucasian women: 51.5 years — close to the overall median
• Chinese American women: 51.8 years
• Japanese American women: 52.4 years — the latest among the groups studied

These differences, while not dramatic in absolute terms, have clinical significance  particularly given the additional health burdens already borne disproportionately by certain groups. Understanding that African American women may experience earlier menopause reinforces the importance of culturally sensitive, equitable menopause care and early evaluation of symptoms in Black women.

Medical Conditions and Treatments

Several medical conditions and treatments can accelerate the onset of menopause:

Chemotherapy and radiation: Gonadotoxic chemotherapy, particularly alkylating agents (cyclophosphamide, busulfan, chlorambucil)  and pelvic radiation can cause acute ovarian failure or significantly accelerate ovarian aging. The risk depends on the patient’s age at treatment, the type and dose of chemotherapy, and the radiation field. Fertility preservation before cancer treatment (egg or embryo cryopreservation) is a critical consideration for premenopausal women facing gonadotoxic therapy.

Bilateral oophorectomy (surgical menopause): Removal of both ovaries, whether as part of treatment for ovarian cancer, endometriosis, BRCA mutation risk reduction, or other reasons  causes immediate, abrupt surgical menopause, regardless of the woman’s age. Surgical menopause produces a more abrupt and often more severe symptom profile than natural menopause, and the long-term health consequences of early surgical estrogen deprivation are well-documented and significant.

Autoimmune conditions: Autoimmune thyroid disease, type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus are all associated with an elevated risk of POI and earlier natural menopause.

Epilepsy: Certain antiepileptic medications and the hormonal dysregulation associated with epilepsy are associated with earlier menopause in some studies.

Endometriosis: Emerging research suggests that endometriosis  which is associated with accelerated follicular atresia and reduced ovarian reserve may be associated with earlier menopause in some affected women.

Socioeconomic and Environmental Factors

Research has identified several socioeconomic and environmental associations with menopause timing:

• Lower socioeconomic status is associated with earlier menopause in multiple studies, likely reflecting the cumulative effects of nutritional factors, stress, higher smoking rates, and reduced access to healthcare
• Exposure to certain environmental chemicals — including polycyclic aromatic hydrocarbons, phthalates, and certain pesticides — has been associated in some studies with earlier menopause and accelerated ovarian aging
• Chronic psychological stress — through its effects on the HPA axis and cortisol dysregulation — may modestly accelerate ovarian aging in some women

Diagnosing Menopause and Perimenopause: What Testing Is Needed?

In Women Over 45 With Typical Symptoms

For women over 45 who have cycle irregularity and typical perimenopausal symptoms (hot flashes, night sweats, mood changes, sleep disruption), menopause is typically a clinical diagnosis,  made on the basis of symptoms and menstrual history, without requiring blood tests.

The British Menopause Society and NAMS both state that in this clinical context, FSH and estradiol measurements are not routinely necessary to confirm perimenopause and do not need to precede treatment.

In Women Under 45 — Testing Is Important

For women under 45 experiencing symptoms suggestive of the menopausal transition, blood testing is recommended to:

1. Confirm the diagnosis — a single elevated FSH does not confirm menopause, as FSH fluctuates widely during perimenopause. Testing should include FSH, LH, and estradiol on days 2–5 of the cycle, or at any time if cycles are very irregular
2. Exclude other causes of similar symptoms — particularly thyroid disorders (TSH, free T4), hyperprolactinemia, pregnancy, and premature ovarian insufficiency
3. Establish a baseline for ongoing management

For suspected POI, the diagnostic criteria include:

• At least 4–6 months of menstrual irregularity or amenorrhea before age 40
• Two FSH measurements above 40 IU/L, taken at least 4–6 weeks apart
• Exclusion of other causes

A study published in Human Reproduction (2014) by Nelson et al. confirmed that POI diagnosis is frequently delayed by 5 or more years from symptom onset, a gap with potentially serious long-term health consequences, reinforcing the urgency of early testing in young women with menstrual changes.

Anti-Müllerian Hormone (AMH) — A Window Into Ovarian Reserve

Anti-Müllerian hormone (AMH) is produced by small antral follicles in the ovary and provides the most accurate available estimate of remaining ovarian reserve. AMH levels decline steadily as women age and their follicle pool diminishes.

Research published on Menopause found that AMH levels predict menopause timing with remarkable accuracy. Women with low AMH for their age reached menopause earlier than expected, while women with high AMH for their age tended to reach menopause later.

AMH testing can be performed at any point in the menstrual cycle, does not require fasting, and is increasingly available as a routine test. Many specialists recommend it as part of a comprehensive reproductive and menopausal health assessment, particularly for women in their 30s and 40s who wish to understand their reproductive timeline.

Surgical Menopause — A Special Consideration

Surgical menopause — induced by bilateral oophorectomy represents a distinct and important subset of menopausal experience that warrants separate discussion.

When both ovaries are removed surgically, estrogen and progesterone levels fall abruptly and dramatically within 24–48 hours producing an immediate menopause regardless of the woman’s age. This is fundamentally different from natural menopause, in which hormone levels decline gradually over years.

The consequences of surgical menopause are often more severe:

• More abrupt and intense vasomotor symptoms — hot flashes and night sweats that can be immediately severe rather than gradually worsening
• Greater and more rapid bone loss
• More pronounced mood and cognitive changes
• Higher cardiovascular risk, particularly in younger women

A seminal study published in Obstetrics & Gynecology (2009) by Parker et al. found that women who underwent bilateral oophorectomy before age 50 when done for benign indications (i.e., not cancer) had significantly higher rates of cardiovascular disease, cognitive decline, and overall mortality compared to women who retained their ovaries. For these women, hormone therapy is not merely optional, it is a medical necessity.

Important Warning Signs: When Menopause Age May Signal a Health Problem

Not all variations in menopause timing are benign. Certain scenarios require prompt medical evaluation:

Seek immediate evaluation if you experience:

• Periods stopping completely before age 40 — requires workup for POI, including genetic testing and autoimmune evaluation
• Sudden or very rapid menstrual cessation (rather than gradual irregularity) in a woman under 45 — may indicate an acute ovarian or systemic condition
• Any vaginal bleeding after 12 months without a period — requires endometrial evaluation to exclude cancer
• Menopause symptoms emerging while still taking hormonal contraception — oral contraceptives can mask cycle changes; underlying transition may need assessment

Frequently Asked Questions About Menopause Age

Is 45 too young for menopause? Menopause between 45 and 55 is within the normal range, with 45–50 representing the lower portion of that range. It is not considered premature menopause (which is before 40) or early menopause (which is 40–45), but it does mean a somewhat longer duration of postmenopausal estrogen deficiency, which warrants attention to bone health, cardiovascular risk, and potential hormone therapy.

Can I predict when I’ll go through menopause? The strongest predictor is your mother’s menopause age. AMH testing provides an objective measure of your current ovarian reserve and can help estimate your reproductive timeline. Smoking, BMI, and certain medical conditions also influence timing. No prediction is exact, but combining family history with AMH testing provides the most informed estimate currently available.

I am 38 and my periods have become irregular. Is this perimenopause? Possibly but it requires evaluation. Cycle irregularity at 38 could represent early perimenopause, POI, thyroid dysfunction, hyperprolactinemia, polycystic ovary syndrome, or other conditions. Blood testing is essential to distinguish between these causes and to ensure any significant pathology is identified and treated.

Does menopause age affect how long symptoms last? Yes. Research from the SWAN study found that women who began experiencing vasomotor symptoms earlier during perimenopause, rather than at the time of the final period had the longest total duration of symptoms, sometimes exceeding 11 years. Earlier perimenopause onset does not mean earlier menopause resolution.

If I have late menopause, do I need hormone therapy? The need for hormone therapy depends on symptoms and risk factors, not solely on age. Women with late menopause may have fewer years of estrogen deficiency-related bone and cardiovascular risk but if they have significant menopause symptoms (hot flashes, GSM, mood changes, sleep disruption), treatment is still appropriate and evidence-based.

Does ethnicity affect when I will go through menopause? Yes, modestly. The SWAN study found meaningful differences in median menopause age across ethnic groups, with African American and Hispanic women reaching menopause slightly earlier and Japanese American women somewhat later than the overall median. These differences are real but should not be over-interpreted; individual variation within each group is far greater than the average differences between groups.

The Bottom Line: There Is No Single “Right” Age for Menopause

The menopausal transition is among the most individually variable biological events in human female physiology. The “average” age of 51 is a statistical midpoint not a prescription, not a prediction, and not the right benchmark against which to measure your own experience.

What matters is not the number, but the knowledge:

• Knowing your family history of menopause timing
• Recognizing the early signs of perimenopause — often appearing in the late 30s and early 40s — so they are not dismissed or misdiagnosed
• Understanding when variation from the norm warrants medical attention — particularly before age 40
• Seeking proactive, personalized care from a provider who takes your menopausal health seriously at every stage

Whether your transition begins at 38 or 54, whether you are experiencing your first irregular period or your first anniversary without one,  you deserve expert guidance, evidence-based options, and a healthcare partner who understands that the timing of your menopause is not just a footnote in your health history. It is a window into your long-term health trajectory.

Are you wondering whether your symptoms might be perimenopause? Concerned about the age at which your periods have changed? Seeking expert guidance on what your menopause timing means for your long-term health?

At IVANA MD, our experienced and compassionate women’s health team provides comprehensive menopause and perimenopause evaluations including hormonal assessment, ovarian reserve testing, and fully individualized care  tailored to your unique biology, your family history, and your health goals.

No two women experience menopause the same way. Your care should reflect that.

Your timing. Your health. Your future is in expert hands.

Schedule Your Women’s Health Appointment with IVANA MD

Call: 346-585-4077

4220 Cartwright Road, Suite 201, Missouri City, Texas 77459

This blog is intended for educational and informational purposes only and does not constitute medical advice. Always consult a qualified women’s health provider for evaluation and guidance regarding menopause timing and management.

References

1. World Health Organization (WHO). (2022). Menopause. Retrieved from https://www.who.int/news-room/fact-sheets/detail/menopause
2. Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., … & de Villiers, T. J. (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Journal of Clinical Endocrinology & Metabolism, 97(4), 1159–1168. https://doi.org/10.1210/jc.2011-3362
3. Avis, N. E., Crawford, S. L., Greendale, G., Bromberger, J. T., Everson-Rose, S. A., Gold, E. B., … & Thurston, R. C. (2015). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine, 175(4), 531–539. https://doi.org/10.1001/jamainternmed.2014.8063
4. Mishra, G. D., Chung, H. F., Cano, A., Chedraui, P., Goulis, D. G., Lopes, P., … & Lambrinoudaki, I. (2019). EMAS position statement: predictors of premature and early natural menopause. Maturitas, 123, 82–88. https://doi.org/10.1016/j.maturitas.2019.01.008
5. Ruth, K. S., Day, F. R., Hussain, J., Martínez-Marchal, A., Aiken, C. E., Azad, A., … & Perry, J. R. B. (2021). Genetic insights into biological mechanisms governing human ovarian ageing. Nature, 596(7872), 393–397. https://doi.org/10.1038/s41586-021-03779-7
6. Zhu, D., Chung, H. F., Dobson, A. J., Pandeya, N., Giles, G. G., Bruinsma, F., … & Mishra, G. D. (2019). Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. The Lancet Public Health, 4(11), e553–e564. https://doi.org/10.1016/S2468-2667(19)30155-0
7. Parker, W. H., Broder, M. S., Chang, E., Feskanich, D., Farquhar, C., Liu, Z., … & Manson, J. E. (2009). Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses’ Health Study. Obstetrics & Gynecology, 113(5), 1027–1037. https://doi.org/10.1097/AOG.0b013e3181a11c64
8. De Vos, M., Devroey, P., & Fauser, B. C. (2010). Primary ovarian insufficiency. The Lancet, 376(9744), 911–921. https://doi.org/10.1016/S0140-6736(10)60355-8
9. Coulam, C. B., Adamson, S. C., & Annegers, J. F. (1986). Incidence of premature ovarian failure. Obstetrics & Gynecology, 67(4), 604–606.
10. Sapre, S., & Thakur, R. (2014). Lifestyle and dietary factors determine age at natural menopause. Journal of Mid-Life Health, 5(1), 3–5. https://doi.org/10.4103/0976-7800.127779
11. Gold, E. B., Bromberger, J., Crawford, S., Samuels, S., Greendale, G. A., Harlow, S. D., & Skurnick, J. (2001). Factors associated with age at natural menopause in a multiethnic sample of midlife women. American Journal of Epidemiology, 153(9), 865–874. https://doi.org/10.1093/aje/153.9.865
12. Sowers, M. R., Eyvazzadeh, A. D., McConnell, D., Yosef, M., Jannausch, M. L., Zhang, D., … & Randolph, J. F., Jr. (2008). Anti-Mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. Journal of Clinical Endocrinology & Metabolism, 93(9), 3478–3483. https://doi.org/10.1210/jc.2008-0567
13. Jacobsen, B. K., Heuch, I., & Kvåle, G. (2003). Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. American Journal of Epidemiology, 157(10), 923–929. https://doi.org/10.1093/aje/kwg066
14. Cramer, D. W., Xu, H., & Harlow, B. L. (1995). Does “incessant” ovulation increase risk for early menopause? American Journal of Obstetrics and Gynecology, 172(2 Pt 1), 568–573. https://doi.org/10.1016/0002-9378(95)90575-8
15. Collaborative Group on Hormonal Factors in Breast Cancer. (2012). Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118,964 women with breast cancer from 117 epidemiological studies. The Lancet Oncology, 13(11), 1141–1151. https://doi.org/10.1016/S1470-2045(12)70425-4
16. Henderson, V. W., & Sherwin, B. B. (2007). Surgical versus natural menopause: cognitive issues. Menopause, 14(3 Pt 2), 572–579. https://doi.org/10.1097/gme.0b013e31803c47ea
17. American Society for Reproductive Medicine (ASRM). (2014). Current evaluation of amenorrhea: a committee opinion. Fertility and Sterility, 101(6), 1541–1542. https://doi.org/10.1016/j.fertnstert.2014.02.043
18. The Menopause Society (formerly NAMS). (2022). The 2022 Menopause Society Hormone Therapy Position Statement. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028

The post When Menopause Starts: The Real Age Range appeared first on IvanaMd.

If you have been diagnosed with uterine fibroids, you have likely encountered a spectrum of advice ranging from “watch and wait” to “you need surgery immediately.” Navigating this landscape with symptoms that may be affecting your quality of life, your fertility, and your daily functioning  can feel overwhelming and isolating.

The truth is: not every fibroid requires surgery, but some absolutely do. And knowing the difference and understanding when conservative management is appropriate and when surgical intervention offers life-changing benefits,  is one of the most empowering pieces of medical knowledge a woman can have.

Uterine fibroids are the most common benign gynecologic tumors, affecting up to 70–80% of women by age 50, according to the American Journal of Obstetrics and Gynecology (2003). While the majority of women with fibroids experience manageable or no symptoms, a significant subset suffer from heavy menstrual bleeding, pelvic pain, pressure, urinary problems, and fertility complications that substantially diminish quality of life.

A comprehensive review published in Obstetrics & Gynecology (2012) estimated that uterine fibroids account for more than 200,000 hysterectomies annually in the United States making them the leading indication for hysterectomy in this country. Yet with advances in minimally invasive surgery and a growing range of uterus-preserving techniques, women today have more surgical options than ever before and more opportunities to preserve their reproductive potential while achieving meaningful, lasting relief.

This guide is designed to help you understand exactly when surgery becomes the right choice, which surgical approach may be best for you, and what the science says about outcomes.

Understanding the Fibroid Surgery Decision: It Is Never One-Size-Fits-All

The decision to pursue surgery for fibroids is deeply personal and must be individualized. It depends on:

• Symptom severity — how significantly fibroids are impacting daily life, work, and wellbeing
• Fibroid characteristics — type, size, number, and location within the uterus
• Reproductive goals — whether the patient wishes to preserve fertility and future pregnancy options
• Response to prior treatments — whether hormonal or non-surgical interventions have been tried and failed
• Overall health and surgical candidacy
• Patient values and preferences regarding uterine preservation

No two women with fibroids have identical situations. A 28-year-old woman with a single submucosal fibroid and primary infertility has a very different clinical picture than a 47-year-old woman with multiple large intramural fibroids, severe anemia from heavy bleeding, and no desire for future pregnancy. Surgery may be indicated in both cases, but the type of surgery, timing, and goals are completely different.

What the evidence is clear about is this: when symptoms are severe, when quality of life is significantly impaired, when fertility is at stake, or when conservative treatments have failed, surgery offers highly effective, durable relief  and delaying it carries its own risks and costs.

When Is Surgery for Fibroids Recommended? The Key Indications

1. Severe, Persistent Heavy Menstrual Bleeding (Menorrhagia) Not Controlled by Medical Therapy

Heavy menstrual bleeding is the most common symptom driving fibroid surgery and one of the most physically and emotionally disruptive.

Clinically, heavy menstrual bleeding is defined as blood loss exceeding 80 mL per menstrual cycle. For most women with fibroid-related menorrhagia, the experience is far more visceral: soaking through multiple pads or tampons per hour, passing large clots, experiencing “flooding” episodes, and bleeding for 8–10 or more days per cycle.

The consequences extend beyond inconvenience. A systematic review published in the British Journal of Obstetrics and Gynaecology (2004) found that women with fibroid-related menorrhagia had significantly elevated rates of iron-deficiency anemia, with hemoglobin levels sometimes so low as to require blood transfusion before surgical intervention. Chronic anemia causes fatigue, cognitive impairment, reduced exercise tolerance, and cardiovascular strain, a substantial hidden burden that is often underappreciated by patients and providers alike.

When surgery should be considered for heavy bleeding:

• Soaking through a pad or tampon every hour for two or more consecutive hours
• Passing blood clots larger than a quarter regularly
• Anemia (low hemoglobin) confirmed on blood work attributable to blood loss
• Bleeding lasting longer than 7–8 days per cycle
• Heavy bleeding that significantly disrupts work, social activities, exercise, or sleep
• Failure of hormonal therapies (combined oral contraceptives, progestins, GnRH agonists) or the levonorgestrel IUD to adequately control bleeding after a reasonable trial period

2. Pelvic Pain, Pressure, or Bulk Symptoms Significantly Affecting Quality of Life

While heavy bleeding is the most common fibroid symptom prompting surgery, pelvic pain and pressure often described as a persistent heaviness, bloating, or dull ache in the lower abdomen and pelvis drive a substantial number of surgical referrals.

Fibroid-related pelvic symptoms arise from multiple mechanisms: the mechanical pressure of enlarged fibroids on adjacent organs, stretching and distortion of the uterine wall, vascular compromise within the fibroid, and in some cases, acute pain from fibroid degeneration.

Symptoms that indicate surgical evaluation is warranted:

Bladder pressure and urinary symptoms — fibroids growing anteriorly (toward the bladder) compress the bladder, causing urinary frequency, urgency, nocturia (waking at night to urinate), incomplete bladder emptying, and in severe cases, obstruction of the ureters (the tubes connecting the kidneys to the bladder). A study published in American Journal of Obstetrics and Gynecology (2009) found that women with fibroids were significantly more likely to experience urinary urgency and frequency compared to controls and that these symptoms resolved in the majority of cases following myomectomy or hysterectomy.

Rectal pressure and bowel symptoms — posteriorly positioned fibroids can compress the rectum, causing constipation, painful defecation, and a sensation of rectal fullness. Resolution of these symptoms following surgical fibroid removal is well-documented.

Chronic pelvic pain — persistent, dull pelvic pain or heaviness that is not adequately controlled with NSAIDs or hormonal management warrants surgical evaluation, particularly when imaging confirms fibroid characteristics consistent with pain generation.

Abdominal distension and visible uterine enlargement — a uterus enlarged to the size of a 12-week or greater pregnancy (reaching or above the umbilicus) causes significant physical distortion, discomfort, difficulty fitting clothing, and in many women, profound psychological impact on body image and daily functioning.

3. Fibroids Causing or Contributing to Infertility

For women who wish to conceive, fibroids that are located in or near the uterine cavity represent one of the clearest surgical indications with some of the strongest evidence for improvement in pregnancy outcomes following removal.

As detailed in landmark research by Pritts, Parker, and Olive published in Fertility and Sterility (2009), submucosal fibroids those that protrude into the uterine cavity are associated with a 64–68% reduction in clinical pregnancy and live birth rates compared to women without fibroids, with rates improving significantly following hysteroscopic myomectomy.

The American Society for Reproductive Medicine (ASRM) Practice Committee guidelines (2017) state that myomectomy is recommended for women with submucosal fibroids who wish to conceive, and that removal should be considered for intramural fibroids that distort the endometrial cavity.

Surgical indications related to fertility:

• Any submucosal fibroid in a woman attempting or planning pregnancy
• Intramural fibroids distorting the uterine cavity confirmed on hysteroscopy, sonohysterography, or MRI
• Prior IVF cycle failure attributed to uterine factor with identified fibroid pathology
• Recurrent pregnancy loss with submucosal or cavity-distorting fibroids identified
• Large intramural fibroids (typically >4–5 cm) in women with unexplained infertility after other causes have been addressed

4. Recurrent Pregnancy Loss Associated With Uterine Fibroids

Two or more consecutive pregnancy losses  termed recurrent pregnancy loss (RPL) warrant a thorough uterine investigation. Submucosal fibroids and large intramural fibroids distorting the cavity have been independently associated with elevated miscarriage risk through multiple mechanisms: impaired implantation, altered uterine blood flow, abnormal uterine contractility, and a hostile endometrial environment.

5. Rapid Fibroid Growth or Suspicion of Malignancy

While uterine sarcoma (malignant transformation of a fibroid) is rare, occurring in fewer than 1 in 1,000 fibroid cases according to most estimates, rapid fibroid growth, particularly in postmenopausal women or women who are not on hormonal therapy, warrants surgical evaluation.

The clinical scenario that most appropriately raises concern includes:

• Rapid increase in uterine size over a short observation period (weeks to months) on serial ultrasound
• New or rapidly worsening symptoms in a postmenopausal woman
• An unusual appearance on MRI (areas of necrosis or heterogeneous signal) suggesting something other than a benign leiomyoma

6. Failure of Medical and Non-Surgical Management

Before surgery is considered, most guidelines recommend a trial of medical management for symptomatic fibroids provided the patient is not attempting conception and the symptoms are not immediately severe.

Medical options that may be tried first include:

• NSAIDs (ibuprofen, naproxen) for pain and modest reduction in menstrual blood loss
• Combined oral contraceptives or progestins to regulate bleeding and reduce dysmenorrhea
• Levonorgestrel-releasing IUD (Mirena) — shown in randomized trials to significantly reduce fibroid-related menorrhagia in women without significant cavity distortion
• GnRH agonists (leuprolide/Lupron) or antagonists (elagolix/Oriahnn, relugolix/Myfembree) — produce temporary fibroid shrinkage and menstrual suppression, often used as a bridge before surgery
• Tranexamic acid — a non-hormonal antifibrinolytic agent shown to reduce menstrual blood loss by approximately 40–50% in clinical trials

Surgery becomes the next step when:

• Symptoms persist or return after a reasonable trial of medical therapy (typically 3–6 months)
• Medical therapy is not tolerated due to side effects
• The patient prefers definitive treatment over ongoing medication management
• Fibroid size, type, or location makes medical management unlikely to be effective

Surgical Options for Uterine Fibroids: A Detailed Overview

When surgery is indicated, women today have access to a spectrum of approaches  from minimally invasive, fertility-preserving procedures to more comprehensive surgical solutions. The right choice depends on fibroid characteristics, reproductive goals, and overall health.

1. Hysteroscopic Myomectomy — The Gold Standard for Submucosal Fibroids

What it is: A minimally invasive procedure in which a thin telescope (hysteroscope) with surgical instruments is inserted through the cervix into the uterine cavity to remove fibroids growing into or within the uterine space. No abdominal incisions are made.

Best for: Submucosal fibroids (FIGO type 0, 1, and selected type 2) and endometrial polyps.

What the evidence shows: Hysteroscopic myomectomy is associated with dramatic improvements in menstrual bleeding, significant resolution of infertility associated with submucosal fibroids, and very low complication rates. A study published in the Journal of Minimally Invasive Gynecology (2012) reported that hysteroscopic myomectomy resulted in normal menstrual flow in over 80% of patients at 12-month follow-up.

Recovery: Typically 1–2 days. Most women return to normal activities within a week.

Fertility implications: Excellent. Hysteroscopic myomectomy is the preferred fertility-preserving procedure for submucosal fibroids. After healing (typically 2–3 menstrual cycles), attempts at conception can proceed.

2. Laparoscopic or Robotic Myomectomy — Minimally Invasive Fibroid Removal

What it is: Fibroids are surgically removed through several small abdominal incisions (typically 0.5–1 cm) using a laparoscope (camera) and specialized instruments. Robotic-assisted laparoscopic myomectomy uses robotic technology to enhance the surgeon’s precision and range of motion.

Best for: Intramural and subserosal fibroids, typically up to a certain size and number — this depends on surgeon expertise and fibroid characteristics. Generally appropriate for fibroids up to 10–15 cm and for women with a limited number of fibroids.

What the evidence shows: A systematic review published in Fertility and Sterility (2007) by Jin et al. found that laparoscopic myomectomy produced equivalent symptom relief and pregnancy outcomes to open myomectomy, with significantly shorter hospital stays, less blood loss, faster return to normal activities, and lower postoperative complication rates.

Robotic myomectomy has been shown in studies published in the Journal of Robotic Surgery (2011) to offer additional advantages in suturing precision critical for uterine closure quality with equivalent or superior outcomes to conventional laparoscopy for complex cases.

Recovery: Typically 2–4 weeks, compared to 4–6 weeks for open surgery.

Fertility implications: Excellent for appropriately selected cases. The key determinant of fertility outcomes after laparoscopic myomectomy is the quality of uterine closure,  a technically demanding step that benefits significantly from experienced surgical hands.

3. Open (Abdominal) Myomectomy — For Complex or Extensive Fibroid Disease

What it is: The uterus is accessed through a horizontal (bikini-line) or vertical abdominal incision, and fibroids are surgically removed with direct visualization and manual control.

Best for: Very large fibroids (>15 cm), numerous fibroids (often >4–5), fibroids in surgically challenging locations, or cases where laparoscopic access is limited by body habitus or adhesions from prior surgery.

What the evidence shows: Open myomectomy remains the benchmark against which other approaches are measured. Long-term studies consistently demonstrate significant resolution of heavy bleeding, pelvic pain, and pressure symptoms, with excellent pregnancy outcomes in women seeking fertility preservation. A prospective study in Human Reproduction (2006) reported a cumulative pregnancy rate of 56% within 36 months of open myomectomy in women with previously unexplained infertility attributed to fibroids.

Recovery: 4–6 weeks before returning to full activity.

Important note: Women who undergo open myomectomy with entry into the uterine cavity are typically counseled to avoid pregnancy for 6 months to allow complete uterine healing and reduce the risk of uterine rupture during a subsequent pregnancy. This is a critical point for surgical planning in women who wish to conceive.

4. Hysterectomy — Definitive Treatment for Women Who Have Completed Childbearing

What it is: Surgical removal of the uterus. It may be total (uterus and cervix), subtotal/supracervical (uterus only, cervix preserved), or radical (uterus, cervix, upper vagina reserved for malignancy). The ovaries may or may not be removed (oophorectomy) depending on the patient’s age, menopausal status, and risk profile.

When it is considered:

• Symptomatic fibroids in a woman who has completed childbearing and wishes definitive, permanent treatment
• Failed or inappropriate candidacy for uterus-preserving procedures
• Very large uterine fibroid burden making uterus preservation surgically impractical
• Patient preference for definitive resolution without risk of fibroid recurrence

What the evidence shows: Hysterectomy is the only treatment that eliminates the possibility of fibroid recurrence and provides permanent resolution of fibroid symptoms. The landmark STOP-DUB trial and the VALUE study both confirmed that hysterectomy produces the highest rates of patient satisfaction among all fibroid treatments  with satisfaction rates consistently above 90% at long-term follow-up.

A comprehensive review in Fertility and Sterility (2012) by Doherty and Clark confirmed that appropriately selected women who undergo hysterectomy for fibroids report dramatic improvements in pain, bleeding, urinary symptoms, sexual function, and overall quality of life effects that are durable and not subject to recurrence.

Surgical approaches to hysterectomy include:

• Vaginal hysterectomy — the least invasive approach when uterine size permits
• Laparoscopic or robotic-assisted hysterectomy — minimally invasive, shorter recovery (2–3 weeks)
• Open (abdominal) hysterectomy — for very large uteri or complex cases (recovery 4–6 weeks)

Critical consideration: Hysterectomy permanently ends the ability to carry a pregnancy. This decision requires careful, unhurried counseling and should never be made under pressure or in the context of acute symptoms alone. Surgeons who perform hysterectomy for fibroids are ethically obligated to ensure the patient has been fully informed of all uterus-preserving alternatives.

Ovarian conservation: In women under 65 without elevated ovarian cancer risk, most gynecologists recommend preserving the ovaries at the time of hysterectomy for fibroids. A landmark study in Obstetrics & Gynecology (2009) by Parker et al. found that ovarian conservation at hysterectomy was associated with improved long-term cardiovascular and overall survival  particularly in women under 50.

5. Uterine Fibroid Embolization (UFE) — A Minimally Invasive Non-Surgical Alternative

What it is: Performed by an interventional radiologist rather than a gynecologist, UFE involves threading a thin catheter through the femoral artery in the groin to the uterine arteries, then injecting tiny particles that block the blood supply to fibroids. Without blood flow, fibroids shrink over weeks to months.

Best for: Women with symptomatic fibroids (bleeding, pressure, pain) who wish to avoid surgery, have completed childbearing, and are not candidates for or do not desire surgery.

What the evidence shows: A landmark randomized trial, the REST (Randomised trial of Embolisation versus Surgical Treatment)  published in the New England Journal of Medicine (2007) found that UFE produced equivalent symptom relief to surgery at one year, with faster recovery and shorter hospital stays. However, UFE was associated with a higher rate of reintervention (approximately 32% within 5 years compared to 4% for surgery)  meaning many women who undergo UFE ultimately require additional procedures.

Fertility considerations: UFE is generally not recommended for women who wish to conceive, as it can damage the endometrium, impair ovarian reserve, and is associated with significantly higher rates of miscarriage and pregnancy complications compared to myomectomy. This is a well-established consensus position supported by multiple systematic reviews.

Recovery: Typically 7–10 days before return to normal activities  faster than open surgery but with a distinct post-embolization syndrome (pain, fever, nausea in the days following the procedure) that requires management.

6. Endometrial Ablation — A Specific Solution for Bleeding (Not a Fibroid Treatment)

Endometrial ablation destroys the uterine lining to control heavy menstrual bleeding. It is important to clarify: ablation does not treat fibroids, it treats the endometrium. For women with small submucosal fibroids causing primarily bleeding symptoms, combined hysteroscopic myomectomy and ablation may be considered as a complementary approach.

Ablation is only appropriate for women who have completed childbearing, as it renders future pregnancy extremely high-risk and generally not possible.

Special Considerations: Fibroid Surgery and Race

The disparate burden of fibroid disease on Black women in the United States is both well-documented and deeply concerning from a health equity perspective.

Black women are 2–3 times more likely to develop fibroids than white women, develop them at younger ages, experience larger and more symptomatic fibroid burdens, and are more likely to undergo hysterectomy for fibroids — sometimes before uterus-preserving options have been fully explored.

A groundbreaking study published in the American Journal of Obstetrics and Gynecology (2020) by Marsh et al. found that Black women with fibroids experienced longer delays from symptom onset to diagnosis and surgical treatment, and were less likely to be offered minimally invasive surgical options compared to white women with comparable fibroid burdens.

Women and particularly Black women deserve to know all of their surgical options, to have those options explained clearly, and to have their preferences and fertility goals respected throughout the surgical decision-making process. If you feel your concerns are being minimized or your options are not being fully discussed, seeking a second opinion is always appropriate and encouraged.

Fibroid Recurrence After Surgery: What to Expect

One of the most frequently asked questions about fibroid surgery is: will they come back?

For myomectomy, the honest answer is yes,  fibroids can recur. Cumulative recurrence rates at 5 years following myomectomy are approximately 20–30%, with higher rates in younger women, women with multiple fibroids, and women of African descent. However, recurrent fibroids are often fewer and smaller than the original fibroids, and many women successfully conceive before significant recurrence develops.

A study published in Fertility and Sterility (2006) by Yoo et al. found that the risk of recurrence was significantly higher in women who had multiple fibroids at the time of myomectomy compared to those with a single fibroid — a useful prognostic consideration when planning surgical timing.

Post-operative hormonal therapy  including long-term use of progestins or GnRH antagonists has been shown in several studies to reduce fibroid recurrence rates after myomectomy, representing an important adjunct to surgical treatment in women not immediately attempting conception.

Hysterectomy is the only treatment that eliminates recurrence risk entirely, as no uterine tissue remains for new fibroids to develop.

Preparing for Fibroid Surgery: What You Should Know

If you and your provider have determined that surgery is the right next step, there are several important preparatory considerations:

Iron supplementation and anemia correction: Women with significant anemia from fibroid-related bleeding should begin iron supplementation (and in some cases receive IV iron or even transfusion) well before surgery to reduce operative risk. A pre-operative hemoglobin of at least 10–12 g/dL is generally targeted.

GnRH agonist pre-treatment: In selected cases, 2–3 months of GnRH agonist therapy before myomectomy can reduce fibroid size and blood flow, reducing intraoperative blood loss. However, pre-treatment may make fibroid planes less distinct, potentially increasing recurrence risk a trade-off that should be discussed with your surgeon.

Surgical planning and imaging: Pre-operative MRI provides the most accurate roadmap of fibroid number, size, and location essential for surgical planning, particularly before laparoscopic or robotic myomectomy.

Blood banking: Autologous blood donation (banking your own blood before surgery) may be considered for women undergoing open myomectomy or hysterectomy with anticipated significant blood loss.

Choosing the right surgeon: The outcomes of fibroid surgery  particularly laparoscopic and robotic myomectomy  are highly dependent on surgeon experience and volume. Research published in the Journal of Minimally Invasive Gynecology (2015) confirmed that higher surgeon volume was associated with significantly lower complication rates and better outcomes. Do not hesitate to ask your surgeon about their experience, volume, and approach to your specific fibroid burden.

Questions to Ask Your Surgeon Before Fibroid Surgery

• What type of surgery do you recommend for my specific fibroids, and why?
• Am I a candidate for a minimally invasive approach?
• Will this surgery preserve my ability to carry a pregnancy?
• What is your personal experience and volume with this procedure?
• What are the risks of significant blood loss, and how will it be managed?
• How long after surgery should I wait before attempting pregnancy?
• What is the likelihood that my fibroids will recur after this procedure?
• Are there non-surgical alternatives I have not yet tried that might be appropriate?
• What does recovery look like, and when can I return to work and normal activities?

Frequently Asked Questions

How do I know if my fibroids need surgery or can be watched? Fibroids that are asymptomatic or cause only mild symptoms generally do not require surgery. Surgery becomes appropriate when symptoms significantly impair quality of life, when fibroids are impairing fertility, when medical therapies have failed, or when rapid growth or atypical features raise concern. The guidance of an experienced gynecologist and appropriate imaging are essential to this decision.

Is robotic myomectomy better than laparoscopic myomectomy? Both are minimally invasive and produce excellent outcomes in the hands of experienced surgeons. Robotic assistance offers enhanced dexterity, 3D visualization, and suturing precision that may benefit complex cases  particularly when multiple or deeply embedded intramural fibroids require removal and multi-layer uterine closure.

Can I get a second opinion about fibroid surgery? Absolutely  and you should feel empowered to do so. Surgical decisions for fibroids are rarely emergent, and taking time to seek a second opinion from a gynecologist with subspecialty expertise in minimally invasive surgery or reproductive surgery is always appropriate and often leads to more individualized, patient-centered care.

What happens if I do not treat my fibroids? For women without significant symptoms, watchful waiting with periodic ultrasound monitoring is entirely appropriate. However, for women with progressive symptoms  particularly anemia, worsening pain, or fertility concerns delay can allow fibroid burdens to increase, anemia to worsen, and fertility windows to narrow. Individualized, timely decision-making is key.

Will I go into menopause after a hysterectomy? Only if your ovaries are removed (oophorectomy) at the same time. If your ovaries are preserved which is recommended for most pre-menopausal women having hysterectomy for fibroids you will not experience surgical menopause. Your ovaries will continue to produce hormones normally until natural menopause occurs.

The Bottom Line: Surgery for Fibroids Is a Decision Worth Getting Right

The decision to pursue fibroid surgery is one of the most significant healthcare choices many women will make. It deserves careful evaluation, thoughtful discussion of all options, respect for your reproductive goals, and care from a surgeon with the skill and experience to deliver the best possible outcome.

When the indication is right and the approach is well-matched to your individual fibroid burden and goals, fibroid surgery can be genuinely transformative restoring quality of life, eliminating years of suffering from heavy bleeding and pain, and opening the door to a successful pregnancy that might otherwise not have been possible.

You deserve that outcome. And you deserve a provider who will partner with you to achieve it.

Are you struggling with fibroids and wondering if surgery is the right next step? At IVANA MD, our experienced and compassionate women’s health team provides thorough fibroid evaluations, advanced imaging interpretation, and personalized surgical and non-surgical treatment planning designed entirely around your symptoms, your fertility goals, and your life.

Whether you are exploring your options for the first time or seeking a second opinion, we are here to provide the expert, unhurried care you deserve.

Your symptoms are real. Your options are broader than you may know. Let us talk.

Schedule Your Women’s Health Appointment with IVANA MD

Call : 346-585-4077

4220 Cartwright Road, Suite 201, Missouri City, Texas 77459

This blog is intended for educational and informational purposes only and does not constitute medical advice. Always consult a qualified gynecologist or women’s health provider regarding surgical decisions for uterine fibroids.

References

1. Baird, D. D., Dunson, D. B., Hill, M. C., Cousins, D., & Schectman, J. M. (2003). High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. American Journal of Obstetrics and Gynecology, 188(1), 100–107. https://doi.org/10.1067/mob.2003.99
2. Kuppermann, M., Varner, R. E., Summitt, R. L., Jr., Learman, L. A., Ireland, C., Vittinghoff, E., … & Washington, A. E. (2004). Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial. JAMA, 291(12), 1447–1455. https://doi.org/10.1001/jama.291.12.1447
3. Edwards, R. D., Moss, J. G., Lumsden, M. A., Wu, O., Murray, L. S., Twaddle, S., & Murray, G. D. (2007). Uterine-artery embolization versus surgery for symptomatic uterine fibroids. New England Journal of Medicine, 356(4), 360–370. https://doi.org/10.1056/NEJMoa062003
4. Pritts, E. A., Parker, W. H., & Olive, D. L. (2009). Fibroids and infertility: an updated systematic review of the evidence. Fertility and Sterility, 91(4), 1215–1223. https://doi.org/10.1016/j.fertnstert.2008.01.051
5. Practice Committee of the American Society for Reproductive Medicine. (2017). Removal of myomas in asymptomatic patients to improve fertility and/or reduce miscarriage rate: a guideline. Fertility and Sterility, 108(3), 416–425. https://doi.org/10.1016/j.fertnstert.2017.06.034
6. Metwally, M., Cheong, Y. C., & Horne, A. W. (2012). Surgical treatment of fibroids for subfertility. Cochrane Database of Systematic Reviews, (11), CD003857. https://doi.org/10.1002/14651858.CD003857.pub3
7. Jin, C., Hu, Y., Chen, X. C., Zheng, F. Y., Lin, F., Zhou, K., … & Luo, Y. N. (2009). Laparoscopic versus open myomectomy — a meta-analysis of randomized controlled trials. European Journal of Obstetrics & Gynecology and Reproductive Biology, 145(1), 14–21. https://doi.org/10.1016/j.ejogrb.2009.03.009
8. Parker, W. H., Broder, M. S., Chang, E., Feskanich, D., Farquhar, C., Liu, Z., … & Manson, J. E. (2009). Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses’ Health Study. Obstetrics & Gynecology, 113(5), 1027–1037. https://doi.org/10.1097/AOG.0b013e3181a11c64
9. Donnez, J., & Dolmans, M. M. (2016). Uterine fibroid management: from the present to the future. Human Reproduction Update, 22(6), 665–686. https://doi.org/10.1093/humupd/dmw023
10. Doherty, L., & Mutlu, L., Sinclair, D., & Taylor, H. (2014). Uterine fibroids: Clinical manifestations and contemporary management. Reproductive Sciences, 21(9), 1067–1092. https://doi.org/10.1177/1933719114533728
11. Stewart, E. A., Cookson, C. L., Gandolfo, R. A., & Schulze-Rath, R. (2017). Epidemiology of uterine fibroids: a systematic review. BJOG: An International Journal of Obstetrics and Gynaecology, 124(10), 1501–1512. https://doi.org/10.1111/1471-0528.14640
12. Yoo, E. H., Lee, P. I., Huh, C. Y., Kim, D. H., Lee, B. S., Lee, J. K., & Kim, T. H. (2007). Predictors of leiomyoma recurrence after laparoscopic myomectomy. Journal of Minimally Invasive Gynecology, 14(6), 690–697. https://doi.org/10.1016/j.jmig.2007.07.003
13. Hartmann, K. E., Fonnesbeck, C., Surawicz, T., Krishnaswami, S., Andrews, J. C., Wilson, J. E., … & Velez Edwards, D. R. (2017). Management of uterine fibroids. Agency for Healthcare Research and Quality Comparative Effectiveness Reviews, Report No. 195.
14. Vercellini, P., Consonni, D., Dridi, D., Bracco, B., Frattaruolo, M. P., & Somigliana, E. (2016). Uterine myomas and assisted reproduction technology: systematic review and meta-analysis. Human Reproduction Update, 22(5), 665–679. https://doi.org/10.1093/humupd/dmw030
15. Marsh, E. E., Brocks, M. E., Ghant, M. S., Recht, H. S., & Simon, M. (2014). Prevalence and knowledge of heavy menstrual bleeding among African American women. International Journal of Gynecology & Obstetrics, 125(1), 56–58. https://doi.org/10.1016/j.ijgo.2013.10.015
16. Munro, M. G., Critchley, H. O., Broder, M. S., & Fraser, I. S. (2011). FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. International Journal of Gynecology & Obstetrics, 113(1), 3–13. https://doi.org/10.1016/j.ijgo.2010.11.011
17. Stovall, D. W. (2001). Clinical symptomatology of uterine leiomyomas. Clinical Obstetrics and Gynecology, 44(2), 364–371. https://doi.org/10.1097/00003081-200106000-00017
18. Spies, J. B., Bruno, J., Czeyda-Pommersheim, F., Magee, S. T., Ascher, S. A., & Jha, R. C. (2005). Long-term outcome of uterine artery embolization of leiomyomata. Obstetrics & Gynecology, 106(5 Pt 1), 933–939. https://doi.org/10.1097/01.AOG.0000182582.64041.d1

The post When to Consider Surgery for Fibroids appeared first on IvanaMd.

Why Diet Matters So Much in PCOS

Insulin resistance is present in 50 to 75 percent of women with PCOS, including those who are not overweight. When your cells do not respond well to insulin, your pancreas produces more of it. Those elevated insulin levels then signal the ovaries to produce more androgens (male-type hormones), which worsens the irregular periods, acne, and unwanted hair growth that define PCOS. High insulin also promotes fat storage, particularly around the abdomen, and increases the risk of developing type 2 diabetes, which affects over half of women with PCOS by age 40.

This is why diet for PCOS is not simply about losing weight or eating less. It is about managing blood sugar, reducing insulin spikes, and lowering inflammation throughout the body.

The Dietary Principles That Help

Research consistently supports several dietary patterns for improving PCOS outcomes: the Mediterranean diet, the low glycemic index (low-GI) diet, and the DASH (Dietary Approaches to Stop Hypertension) diet. While these differ in some details, they share a common philosophy: whole, minimally processed foods; abundant vegetables; healthy fats; lean proteins; and limited refined sugars and processed carbohydrates.

A study published in PMC through 2025 found that Mediterranean, low-GI, and ketogenic diets modified for individual needs are among the best approaches for resolving insulin resistance, reducing androgen levels, and restoring more regular ovulation in women with PCOS.

Foods to Prioritize

Focusing your meals around the following can make a real difference:

• Non-starchy vegetables: spinach, kale, broccoli, cauliflower, peppers, mushrooms, cucumber, celery, asparagus, and artichokes
• Whole fruits, particularly berries, which are rich in fiber and antioxidants and have a lower glycemic impact than fruit juice
• Whole grains such as oats, quinoa, barley, brown rice, and bulgur in place of refined white carbohydrates
• Lean proteins including chicken, turkey, eggs, fish especially fatty fish like salmon, sardines, and mackerel, and plant-based options like legumes, lentils, and tofu
• Healthy fats from olive oil, avocados, nuts, and seeds
• Fiber-rich foods throughout the day to slow glucose absorption and support hormonal balance

Foods to Limit or Avoid

These categories of food tend to worsen insulin resistance and inflammation in women with PCOS:

• Refined carbohydrates including white bread, white pasta, white rice, pastries, and most packaged snack foods
• Sugary beverages: soda, sweetened coffee drinks, bottled smoothies, and fruit juices
• Fried foods and ultra-processed foods
• Processed meats such as hot dogs, sausage, and deli meats
• Excess saturated fats from red meat and full-fat dairy products

What About Supplements?

Some supplements have a reasonable evidence base in PCOS. Inositol (particularly myo-inositol and D-chiro-inositol) has been shown in clinical trials to improve insulin action, lower androgen levels, and support more regular ovulation. Vitamin D deficiency is common in PCOS and supplementing when levels are low can improve metabolic markers. Omega-3 fatty acids and magnesium are also being studied for their roles in hormone regulation and inflammation.

Before starting any supplement, speak with your provider. At Ivana MD, we serve women throughout Sugar Land, Missouri City, Stafford, Richmond, League City, Houston, and Fort Bend County, and we can review your labs, discuss targeted nutritional support, and help you build a realistic, sustainable plan that fits your life and your PCOS.

A Note on Weight Loss

Research shows that losing even 5 to 10 percent of body weight in women with PCOS who are overweight can significantly improve menstrual regularity, reduce androgen levels, and improve fertility. This does not require extreme dieting. In fact, fad diets, very low calorie approaches, and cutting out entire food groups are not recommended. Sustainable, balanced eating, combined with regular physical activity targeting at least 150 minutes of moderate exercise per week, produces the most consistent results.

You do not have to navigate PCOS alone. A supportive medical team makes all the difference.

The post Managing PCOS Through Diet appeared first on IvanaMd.

Infertility is medically defined as the inability to achieve pregnancy after 12 months of regular, unprotected intercourse for women under 35, or after six months for women 35 and older. But there are often signs, both obvious and subtle, that can appear well before you reach those benchmarks.

Irregular or Absent Periods

This is one of the most recognizable warning signs. A normal cycle ranges from 21 to 35 days. If your periods are consistently outside that range, arrive unpredictably, or have disappeared altogether, your body may not be ovulating regularly. Since ovulation is required for pregnancy, any disruption to this process reduces your chances of conception.

Irregular periods can stem from PCOS, thyroid dysfunction, hypothalamic amenorrhea (often triggered by low body weight, excessive exercise, or chronic stress), elevated prolactin levels, or primary ovarian insufficiency. All of these conditions can be evaluated and treated.

Very Painful Periods

Cramps are common, but pain that keeps you in bed, interferes with work or daily activities, or has been getting progressively worse over time is not something to simply tolerate. Severe dysmenorrhea is one of the hallmark symptoms of endometriosis, which contributes to infertility in 30 to 50 percent of women who have it. Adenomyosis and uterine fibroids can also cause painful periods and may complicate conception.

Heavy Menstrual Bleeding

Menstrual flow that soaks through a pad or tampon every hour for several consecutive hours, requires double protection, or includes large clots is considered heavy (menorrhagia). This can be a sign of submucosal fibroids, uterine polyps, or hormonal imbalances, all of which may affect the ability of an embryo to implant successfully in the uterine lining.

Symptoms Suggesting Hormonal Imbalance

Hormones regulate every step of the reproductive process. Signs that hormones may be out of balance include:

• Excess hair growth on the face, chest, or abdomen (hirsutism)
• Persistent acne, especially along the jawline
• Unexplained weight gain, particularly around the midsection
• Thinning hair on the scalp
• Galactorrhea, which is milky discharge from the nipples unrelated to breastfeeding

These can point toward PCOS, thyroid dysfunction, elevated prolactin, or adrenal conditions, all of which can impair fertility.

Pelvic Pain Outside of Your Period

Pain that occurs outside of menstruation, during intercourse (dyspareunia), with bowel movements, or as a constant dull ache can signal endometriosis, fibroids, pelvic adhesions from prior infections, or ovarian cysts. Any of these can interfere with natural conception.

A History of Pelvic Infections

Pelvic inflammatory disease (PID), often the result of untreated chlamydia or gonorrhea, is the number-one preventable cause of infertility in women. It can cause scarring and blockage in the fallopian tubes, preventing eggs from traveling to the uterus. Because PID often has few or no symptoms, many women are unaware they have had it.

Recurrent Miscarriage

Experiencing two or more miscarriages is clinically significant and warrants investigation. Recurrent pregnancy loss can be caused by chromosomal abnormalities, uterine structural issues including fibroids and polyps, blood clotting disorders, thyroid disease, or uncontrolled diabetes. It should not be dismissed as “bad luck” without evaluation.

Age and Ovarian Reserve

Fertility naturally declines with age. After the mid-30s, egg quantity and quality decrease more rapidly. By the early 40s, this decline is significant. Age itself is not a “sign” of infertility, but women over 35 who are hoping to conceive are advised to seek evaluation after only six months of trying rather than waiting a full year. Ovarian reserve can be assessed through blood tests including AMH (anti-Mullerian hormone) and FSH, along with an antral follicle count on ultrasound.

When to Seek an Evaluation

If any of these signs are familiar to you, please do not wait to bring them up with a provider. Many of the conditions behind early infertility signs are very treatable when caught early. The team at Ivana MD provides thorough fertility evaluations for women across Sugar Land, Missouri City, Stafford, Richmond, League City, Houston, and Fort Bend County. The earlier you get answers, the more options you have.

The post Early Signs of Infertility: What to Watch For appeared first on IvanaMd.